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Treatment of severe mitral regurgitation 
with MitraClip system  
— a single-centre study
ABSTRACT
Introduction. MitraClip (MC) is a catheter-based device to treat mitral regurgitation (MR). This method 
uses a transseptal approach and is based on the creation of a double orifice mitral valve by suturing of 
the middle scallops of the mitral valve’s leaflets.
Aim. The aim of the study was to assess the effectiveness of MC method in treating patients with severe 
MR. We analysed MR severity, patient’s clinical condition evaluated by New York Heart Association (NYHA) 
functional class, and the function of the left ventricle evaluated by Left Ventricle Ejection Fraction (LVEF). 
Methods. A retrospective single-centre study with patients hospitalised at the Department of Cardiology and 
Internal Medicine in Bydgoszcz. All diagnosed with severe MR and treated by performing MC procedure 
in the time period from August 2010 to December 2014. The following data from medical history (NYHA 
class) and echocardiography examinations (MR severity and LVEF) were analysed in three time points: 
before, right after the procedure, and after the follow-up period (four weeks since discharge).
Results. The studied group consisted of 11 patients — 8 male, 3 female, aged 64.4 ( ± 10.2) years, treated 
with MC. All of the three analysed parameters improved relevantly as a result of the evaluated procedure. 
The percentage of patients classified as NYHA class III/IV presents as follows: 90% before the procedure, 
55% after MC implantation (ns), and 44% after the follow-up period (p = 0.01). All patients suffered from 
severe-to-moderate (3+) and severe (4+) MR before the procedure. After implantation only 9% (ns) were 
still classified with 3+/4+ MR, and after the follow-up this percentage reached 18% (p = 0.0005). We 
observed relevant changes of LVEF. The average LVEF at baseline was 27.9 ± 2%, which increased to 
29.6 ± 2% (ns) after the MC implantation and 34 ± 7% (p = 0.02) after the follow-up. 
Conclusion. MC therapy is effective in patients with severe symptomatic MR with congestive heart failure 
and decreased LVEF. It reduces MR severity both acutely and after the follow-up period and improves 
NYHA class and LVEF.
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Introduction
Mitral regurgitation (MR) is the second most com-
mon valvular heart disease requiring surgery in Europe 
after aortic stenosis [1]. We can single out two types of 
MR. The first one is degenerative MR, which is caused 
by changes of the valvular apparatus. The second one 
is called functional MR and develops in a result of re-
modelling of the left ventricle (LV) usually in the course 
of ischaemic heart disease [2]. MR incidence increases 
with age. It has become a serious clinical problem due 
to the ageing of the general population. Symptomatic 
severe MR or asymptomatic severe MR complicated by 
LV dysfunction requires surgical repair or replacement 
of the mitral valve (MV). Elderly patients with moder-
ate-to-severe or severe MR are at high or prohibitive 
surgical risk caused by advanced age, the presence 
of comorbidities, or impaired LV function. Morbidity 
and mortality are directly related to MR severity among 
patients with heart failure and depressed left ventricular 
ejection fraction (LVEF).
MitraClip (MC) is a catheter-based device designed 
to perform edge-to-edge reconstruction of MV [3]. This 
method uses a transseptal approach and is based on 
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the creation of a mitral double orifice valve by suturing 
of the anterior and posterior MV leaflets. As a result the 
leaflets are closer during systole, thereby reducing the 
amount of regurgitation [1].
The EVEREST I (Endovascular Valve Edge-to-Edge 
Repair Study I) demonstrated the safety, feasibility, 
and significant haemodynamic improvement of the MC 
procedure [1]. In the EVEREST II (Endovascular Valve 
Edge-to-Edge Repair Study II) study 279 patients with 
moderate to severe MR were randomised 2:1 either to 
MC implantation or open heart surgical valve repair [4]. 
At 12-month follow-up 55% of patients in the MC 
arm were free from death, surgery, or grade 3+ and 4+ 
MR as compared to 73% of patients in the surgery group 
[4]. Moreover, after the follow-up period 13% of surgical 
patients were in functional New York Heart Association 
(NYHA) class III or IV while in the MC group it was only 
2% of patients [5]. Major adverse events assessed in the 
EVEREST II study were as follows: death, myocardial 
infarction (MI), reoperation for failed surgical repair or 
replacement, urgent or emergency cardiovascular sur-
gery for adverse event, major stroke, renal failure, deep 
wound infection, mechanical ventilation for > 48 hours, 
gastrointestinal complication requiring surgery, new 
onset of permanent atrial fibrillation, septicaemia, and 
transfusion of ≥ 2 units of blood. Major adverse events 
occurred commonly in the surgery group (48% vs. 15%, 
p < 0.001) 30 days after the procedure [5]. The differ-
ence was mainly driven by the need for transfusion and 
prolonged mechanical ventilation. Therefore the MC 
technique has evolved into a therapeutic alternative 
for patients with significant MR of both degenerative 
and functional origin, whose surgical risk is considered 
prohibitive. 
The aim of our study was to assess the reduction 
of MR severity in patients with severe symptomatic MR 
after performing the MC procedure. We also analysed 
the clinical condition of patients assessed by NYHA 
class and evaluated the function of LV with echocardio-
graphy by measuring LVEF. 
Materials and methods
We conducted a retrospective single-centre study 
and enrolled patients hospitalised at the Department 
of Cardiology and Internal Medicine in Bydgoszcz, 
diagnosed with severe MR and treated by implantation 
of MC system in the time period from August 2010 to 
December 2014. 
All patients included in the study had severe, 
symptomatic MR. The aetiology of MR was functional, 
associated with the remodelling and significant dys-
function of LV. 
Patients with a history of recent MI, acute endo-
carditis, or rheumatic heart disease were excluded 
from the procedure. Other exclusion criteria were 
the anatomic contraindications evaluated by echo-
cardiography such as coaptation length of MV leaf-
lets < 2 mm, coaptation depth of MV leaflets > 11 mm, 
mitral valve area < 4 cm2, flail gap > 10 mm, flail 
width > 15 mm, left ventricular end-systolic diameter 
(LVESd) > 55 mm, and massive calcifications of the 
valvular apparatus. 
The heart team qualified all patients for the proce-
dure. Both transthoracic and transoesophageal echo-
cardiography examinations were performed before the 
procedure to assess the aetiology and mechanism of 
MR. Severity of MR was also graded by echocardiog-
raphy. Severe MR was identified based on the criteria 
recommended by the European Association of Echo-
cardiography [6]: vena contracta ≥ 7 mm, regurgitant 
volume ≥ 30 mL/beat (for functional MR), effective regur-
gitant orifice area ≥ 0.2 cm2 (for functional MR), E wave 
dominant > 1.5 m/s, TVI mitral/TVI aortic (Time-Velocity 
Integral ratio) > 1.4, and systolic reversal in pulmonary 
veins. The biplane Simpson’s method was used to 
measure volumes of LV and LVEF. 
MC procedure was performed in an adapted hae-
modynamic lab using monitoring by transoesophageal 
echocardiography and fluoroscopy. The team should 
consist of a cardiologist, echocardiographer, anaesthe-
siologist, and cardiac surgeon.
Whole procedure included four stages. In the first 
stage the catheter was introduced through the femoral 
vein into the right atrium, and the septum was punc-
tured. In the next stage, the catheter with the implant 
was positioned in the distal part of the left atrium, one 
centimetre above the MV. Subsequently, the opened 
implant was entered to the LV and it was positioned in 
the coaptation line. All corrections were made under 
the control of echocardiography. The implant was 
pulled into the left atrium and two leaflets of the MV 
were grabbed. Finally, the implant was closed and 
released, the catheter was removed. In the event of 
failure to obtain a satisfactory result, it was possible 
to use two or three implants [1]. The first successful 
implantation of four MC devices in Poland in a patient 
with severe, symptomatic MR was performed in Byd-
goszcz [7]. 
Acute procedural success (APS) was defined as the 
reduction of MR severity to grade 2+ or lower after the 
clip implantation graded by echocardiography [9–16].
All data (collected from the medical history, dis-
charge summary, and echocardiography examination) 
were analysed in three time points: before the proce-
dure, right after the procedure, and after the follow-up 
period (four weeks after discharge). We used  Statistica 
Soft version 12.5 software. Parametric values such as 
LVEF were compared using Student’s t-test. Non-para-
metric values such as NYHA class were compared using 
Wilcoxon signed-rank test.
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Table 1. Baseline characteristics of patients
n = 11 %
Demographic
Age (years) 64 ± 10 –
Sex
   Female 3 27
   Male 8 73
Comorbidities
Prior myocardial infarction 6 55
CABG 3 27
PCI
   Overall 5 45
   LAD 2 18
   RCA 1 9
   LAD+Cx 1 9
   LAD+RCA 1 9
Previous stroke 2 18
TIA 0 0
Arterial hypertension 4 36
Atrial fibrillation 2 18
Prior cardiac surgery 6 55
ICD/CRTD 5 45
Hypercholesterolaemia 2 18
DM 6 55
COPD 2 18
Chronic renal disease 3 27
Hypothyroidism 3 27
Gout 2 18
Cancer 0 0
Table 2. Baseline characteristics of echocardiography 
parameters
n = 11 %
LVEF ± SD (%) 29 ± 8
LVEF < 40% 9 82
Aetiology of MRc
   Ischaemic 5 45
   Non-ischaemic 6 55
Number of regurgitant jets (n = 9)
   1 3 33
   2 6 67
Vena contracta ± SD [cm] (n = 9) 0.83 ± 0.12 –
MR severity 4+ 11 100
RVSP (SPAP) ± SD [mm Hg] (n = 8) 57 ± 20 –
Results
The analysed group consisted of 11 patients (8 male 
and 3 female) treated with MC system. The average 
age of the patients stood at 64.36 (± 10.2) years and 
ranged from 48 to 81 years. Before procedure 90% of 
patients were classified as III/IV NYHA class. Baseline 
characteristics of patients and their comorbidities are 
provided in Table 1.
The aetiology of MR was described as non-isch-
aemic in four patients (36%) and as ischaemic in 
seven of them (64%). MR severity in all of the studied 
cases was described as severe (4+) before procedure 
(Tab. 2). During the procedure five patients had one 
clip implanted and six of them had two clips. As the 
follow-up we defined control examination performed 
43 ± 25 days after the procedure, i.e. approximately 
four weeks after discharge.
All of the patients suffered from severe (4+) MR. 
APS was achieved in 91% of the patients. At the follow 
up 82% had MR severity ≤+2. A comparison of MR 
severity before and after the procedure is presented 
below (Fig. 1).
Table 3 shows the changes of the most relevant 
echocardiography parameters observed before the 
procedure and after the follow-up.
Right after the MC implantation the percentage of 
patients classified as III/IV NYHA class reached 55%. 
After the follow-up patients with NYHA III/IV class made 
up only 44% of treated group (Fig. 2).
LVEF increased significantly from 27.9 ± 2 % before, 
to 29.6 ± 2% after the procedure. After the follow-up the 
average LVEF stood at 34 ± 7% (p = 0.022) (Fig. 3). 
Discussion 
To the best of our knowledge this is the first polish 
study revealing the effects of treatment with MC system 
in more than 10 patients. Other descriptions discussed 
up to three cases [2, 8]. In our study the follow-up period 
lasted 43 ± 25 days and we analysed the changes of 
three main parameters: NYHA class, MR severity, and 
LVEF. We compared our results with other registries 
(mainly European) which differed with the number of 
patients, the length of follow-up period, the average 
age, and the percentage of patients who suffered from 
prior MI, arterial hypertension, and DM. The compared 
registries included more patients (from 20 to 567) than 
in our study and the follow-up period lasted longer. The 
group in our study was younger (the average age was 
64 years) than the groups from compared studies where 
the average age was between 70 and 78 years [9–16]. 
In our group 55% of patients suffered from prior MI, 
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Figure 1. Comparison of MR severity before and after MC implantation, and after follow-up
Table 3. Comparison of echocardiography parameters before MC and after follow-up
Before MC After follow-up
LVEF ± SD (%) 29 ± 8 34 ± 7
Vena contracta ± SD [cm] 0.83 ± 0.12 0.48 ± 0.15
MR severity 1+ (% of patients) 0 18
MR severity 2+ (% of patients) 0 64
MR severity 3+ (% of patients) 0 18
MR severity 4+ (% of patients) 100 0
Figure 2. Comparison of percentage of patients in NYHA class before and after MC implantation, and after follow-up; 
III — NYHA III class; IV — NYHA IV class
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34.4% from arterial hypertension, and 55% from DM. 
In compared registries patients more often had arte-
rial hypertension: from 64 to 85% [11, 13, 14, 16] of 
patients, but the percentage of prior MI and DM was 
lower — from 21 to 32% for MI [10, 11, 13] and 18 to 
40% for DM [10, 11, 13, 14, 16]. The high percentage 
of patients who had undergone prior MI is connected 
with the aetiology of MR in our group. All our patients 
had functional MR and for the majority of them the 
aetiology was described as ischaemic. However, we 
confronted our results independently from the aetiology 
of MR. The majority of compared registries included 
patients mainly with functional MR except that from 
Feldman et al., who studied the group with mainly 
degenerative MR [16] and Gaemperli et al. [11] where 
the groups were similar: 45% with functional and 48% 
with degenerative MR. 
MC therapy reduced MR severity. APS was achieved 
in 10 cases (91%). Other studies showed similar results: 
APS between 73 and 94% [9–16]. We confronted the 
percentage of patients with MR severity ≤ 2+ after the 
follow-up period (82% in our study) with other results 
and they were comparable to ours. Franzen et al. [9] 
and Gaemperli et al. [11] reported higher reduction of 
severity — 87% and 86%, while lower was recorded by 
Koifman et al. [14] — 64%, Feldman et al. [16] — 66%, the 
registry from Switzerland [15] — 58%, the registry from 
France [12] — 80%, and the ACCESS-EU registry [13] 
— 78.9%. All compared registries were characterised 
by longer follow-up periods, which lasted from 69 days 
to two years.
NYHA class significantly improved after the follow-up 
period; 44% of patients stayed in class III or IV. Com-
pared to the other reports this percentage is higher. 
Koifman et al. [14] reported 90% of patients in class III 
or IV NYHA before the procedure, which reduced to 41% 
after 187 days, and Franzen et al. [9] showed reduction 
from 100% to 28% after six months of follow-up. In 
TRAMI registry [10] the follow-up period lasted 85 days 
and the same parameter decreased from 93% to 36%. 
In the registry from Switzerland [15] there were about 
80% (no clear information) of patients in class III or IV 
NYHA before the implantation, and two years after the 
procedure there were 22%. The registry from France [12] 
and ACCESS-EU registry [13] reported as follows: the 
reduction from 77% to 9% and from 84.9% to 28.6% six 
months and 12 months after the procedure, respective-
ly. Also the study by Feldman et al. [16] showed that at 
baseline there were 55% and only 8% of patients stayed 
in class III or IV NYHA after 12 months.
We observed that LVEF increased acutely after the 
procedure and after the follow-up period. The LVEF 
improved from the baseline value 27.9 ± 2% to 34 ± 7% 
after the follow-up period, which was statistically signifi-
cant (p = 0.02). Interestingly, only one of the compared 
studies showed a similar effect. It was the study by 
Franzen et al. [9] where they analysed a group of pa-
tients with end-stage heart failure — all patients were in 
III or IV NYHA class and had LVEF ≤ 25%. The majority 
had severely dilated hearts (LVESd > 55 mm present 
in 78%). In this group LVEF increased from 20 ± 4% to 
25 ± 9% (p = 0.003). All patients had functional MR in 
this study. Unfortunately, the study in which patients had 
mainly degenerative MR [16] did not reveal the changes 
of LVEF after the follow-up period. LVEF decreased or 
stayed stable at the follow-up in the rest of the compared 
registries. They presented a similar percentage of pa-
tients with functional MR (from 62 to 73,8%) but all of 
them differ from our study with higher baseline values of 
LVEF (from 36 to 47%) [12, 14, 15]. The highest baseline 
LVEF values were reported in the same study in which 
the percentage of patients with degenerative MR was 
the highest. However, Gaemperli et al. [11] indicate that 
even though LVEF was decreased in those cases, the 
LV contractility would be insignificantly affected due to 
load independent parameters. 
As mentioned before, as many patients as present-
ed in this study were not described in any other Polish 
publication. Two publications reported six cases of 
performing MC procedure in patients with severe MR. 
The first one, by Kalarus et al. [8], showed the results 
of implanting clips in three patients with severe (4+) 
ischaemic MR and high cardio surgical risk. All three 
patients were in class III or IV NYHA and had a history 
of prior MI and previous revascularisation proce-
dures. Also, LVEF was impaired and ranged from 23 to 
28%. On the fifth day after the procedure the researchers 
observed a reduction in MR severity and improvement 
of NYHA class and LVEF. The results five days after the 
procedure showed that MR severity decreased to ≤ 2+ 
in all three cases. All patients were in class II NYHA and 
their LVEF also increased and was between 25 and 
33%. The second study, by Kübler et al. [2], presented 
results of performing MC procedure in three cases with 
a 90-day follow-up period. Also in this study all patients 
suffered from significant (3+/4+) ischaemic MR and 
were excluded from surgery due to high cardio surgical 
risk. Before the procedure two patients were in class III 
Figure 3. Comparison of LVEF (%) before and after MC 
implantation, and after follow-up
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NYHA and the third was in class III/IV. LVEF was 18%, 
28%, and 25%, respectively. After 90 days of follow-up 
the MR severity reduced in two patients to ≤ +2 and in 
one patient quite severe (2+/3+) MR persisted. Exer-
cise capacity assessed by NYHA class improved in all 
patients — two of them were in class II and the third 
one was in class II/III. Also, LVEF increased to 25% in 
one patient and to 30% in the other two. Due to the 
very small number of patients and the lack of statistical 
analysis comparison with our results is futile, although 
patients reported in those studies presented similar 
clinical condition and comorbidities to our patients. 
The differences between our study and the other 
registries may be a result of the aetiology of MR. In our 
study all patients had functional MR, and 64% of patients 
in that group had ischaemic MR. It seems that the reduc-
tion of MR severity with MC procedure is independent 
of the aetiology of MR because both Franzen et al. [9] 
(100% with functional MR) and Gaemperli et al. [11] 
(only 45% with functional MR) reported similar reduction 
of severity — 87% and 86%, respectively. However, 
LVEF is strongly associated with the aetiology of MR 
— patients with functional MR usually had much lower 
LVEF than those with degenerative MR. Furthermore, 
both studies with only functional MR (ours and the 
study by Franzen et al. [9]) showed the same result 
— an improvement in LVEF after the follow-up period. 
Both groups had much lower baseline values of LVEF 
in comparison to other registries. We may assume that 
the improvement of LVEF after the follow-up period was 
a result of LV remodelling in patients with functional MR. 
Probably the fact that more patients had degenerative 
MR in other studies resulted in stable or even decreased 
LVEF after the follow-up period. The effect of remodel-
ling in patients with degenerative MR is less noticeable 
because they had efficient LV. That is the reason why 
after reducing MR severity their LVEF stayed stable. 
LVEF could even decrease, especially in patients who 
were in the hyper-compensation phase of MR while the 
procedure took place. 
The shorter follow-up period may also be a cause 
of differences between our study and the others. The 
longer follow-up period would probably not affect the 
reduction of MR, which  was presented in the registry 
from Switzerland [15], where the percentage of patients 
with MR severity ≤ +2 was almost the same after one 
year and after two years of observation. MR severity 
worsened only in one patient during the second year. 
We may expect that the longer follow-up period would 
result in greater improvement of LVEF and NYHA class 
because patients with functional MR would have more 
time for beneficial remodelling of LV. However, improve-
ment of NYHA could be inhibited by comorbidities, for 
example coronary artery disease, which is common in 
patients with functional MR.
The younger age of our patients should lead to 
greater improvement of clinical condition expressed 
by NYHA class based on the assumption that younger 
patient equals better overall condition. On the other 
hand, a higher percentage of patients in our group 
had history of prior MI and DM. It seems that those 
comorbidities could inhibited the improvement of NYHA 
class and led to differences between our study and the 
other registries.
Limitations of the study
In our opinion the main limitation of this study is 
the low number of patients and short follow-up period. 
Furthermore, the retrospective character inhibited us 
from gathering all essential data needed.
Conclusion
Patients suffering from severe symptomatic MR with 
heart failure and impaired LV function (decreased LVEF) 
can be successfully treated with the MC procedure. The 
MC procedure reduces the severity of MR in the majority 
of cases not only acutely after the procedure (APS in 
91%) but also after the follow-up period (82%). It also 
led to the improvement of both NYHA class and LVEF. 
It proves that it can be an effective therapy for patients 
whose cardio surgical risk is considered prohibitive. 
Definitely further investigation, especially randomised, 
prospective trails, are needed.
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